Foghorn Therapeutics
Charles Allerton III is the Owner and Principal Consultant at Neon Fox Consulting, LLC, where the focus is on assisting biotech and pharmaceutical clients in establishing effective supplier partnerships aligned with strategic business goals. Allerton has extensive experience in strategic sourcing leadership, having worked with various biotech companies since 2020 to implement R&D sourcing initiatives and procurement strategies. Previous roles include Principal Consultant positions at Foghorn Therapeutics Inc., Scholar Rock, and Esperion, along with significant contributions at Axovant Gene Therapies Ltd. and AMAG Pharmaceuticals in developing procurement capabilities and strategies. Earlier in his career, Allerton held positions at Biogen, Johnson & Johnson, and Bristol-Myers Squibb, contributing to sourcing, supplier management, and IT investment management with a strong emphasis on cost savings and operational efficiency. Allerton holds an MBA and MHA from the University of Pittsburgh and a Bachelor of Arts in Pre-Medicine from the same institution.
This person is not in any teams
This person is not in any offices
Foghorn Therapeutics
1 followers
Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Their proprietary Gene Traffic Control platform gives them an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing them to identify, validate, and potential drug targets within the system.